Morgan Stanley analyst Michael Ulz initiated coverage of Dyne Therapeutics with an Overweight rating and $40 price target. The analyst believes initial data across the company’s co-lead programs, DYNE-101 and DYNE-251, validates the broad potential of the Force platform in serious muscle diseases. The firm expects updated data in the second half of 2024 to drive continued share momentum.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
- Dyne Therapeutics Welcomes John Cox as New CEO and Board Member
- Dyne Therapeutics CEO Joshua Brumm to step down, John Cox to succeed
- Dyne Therapeutics Announces CEO Transition
- Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days
